Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplant and Dietary Fiber Supplementation in Graft Versus Host Disease
NCT05067595Phase 1Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Fecal Microbiota Transplantation Capsule in Graft-versus-host disease of the gastrointestinal tract (4 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Bacterial composition of stool, Bacterial genes in stool and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
Graft-versus-host disease of the gastrointestinal tract
Beyond the preview
Go deeper on NCT05067595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067595.